Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel S Merseburger

Showing results (101-110 of 323) with videos related to

Pageof 33
Sort By:
Aktuelle Urologie|February 1, 2021
[Intravesical Gemcitabine instillations following BCG failure and allergy to Mitomycin: A unique case of a patient with an inverted papilloma of the bladder]Merle Matzen, Anne Offermann, Lars Tharun, et al.
Aktuelle Urologie|August 8, 2018
[Practice Pattern of Systemic Therapy for Urothelial Cancer in Germany - A Survey of the German Cancer Society]Marie Christine Hupe, Axel S Merseburger, Maike de Wit, et al.
World Journal of Urology|June 24, 2018
The BET-inhibitor PFI-1 diminishes AR/AR-V7 signaling in prostate cancer cellsMarie C Hupe, M Raschid Hoda, Friedemann Zengerling, et al.
Urologia Internationalis|July 14, 2007
Cathepsin D serum levels are not a valid serum marker in renal cell carcinomaAxel S Merseburger, Joerg Hennenlotter, Arnulf Stenzl, et al.
Aktuelle Urologie|November 11, 2025
[New Prostate Cancer Guideline: Is Biopsy of PI-RADS 3 Lesions Meaningful? The Role of Multiparametric MRI-Ultrasound Fusion Biopsy in Detecting Clinically Significant Prostate Cancer]Paul Schildhauer, Marten Müller, Axel S Merseburger, et al.
Immunotherapy|July 20, 2010
Present state of target therapy for disseminated renal cell carcinomaSandra Waalkes, Mario Kramer, Thomas Rw Herrmann, et al.
Advances in Therapy|December 5, 2020
Hemopatch<sup>®</sup> as a Hemostatic Agent is Safe in Partial Nephrectomy: A Large, Single-Surgeon Retrospective EvaluationMarie C Hupe, Maximilian Büttner, Pouriya Faraj Tabrizi, et al.
World Journal of Urology|July 9, 2011
Natural orifice (NOTES) transurethral sutureless radical prostatectomy with thulium laser support: first patient reportUdo Nagele, Aristotelis G Anastasiadis, Ute Walcher, et al.
Oncology Letters|September 12, 2012
Maspin protein expression correlates with tumor progression in non-muscle invasive bladder cancerMario W Kramer, Sandra Waalkes, Jörg Hennenlotter, et al.
World Journal of Urology|September 28, 2014
Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?Axel S Merseburger, Peter Hammerer, Francois Rozet, et al.
Pageof 33

Showing results (101-110 of 323) with videos related to

Sort By:
Pageof 33
Aktuelle Urologie|February 1, 2021
[Intravesical Gemcitabine instillations following BCG failure and allergy to Mitomycin: A unique case of a patient with an inverted papilloma of the bladder]Merle Matzen, Anne Offermann, Lars Tharun, et al.
Aktuelle Urologie|August 8, 2018
[Practice Pattern of Systemic Therapy for Urothelial Cancer in Germany - A Survey of the German Cancer Society]Marie Christine Hupe, Axel S Merseburger, Maike de Wit, et al.
World Journal of Urology|June 24, 2018
The BET-inhibitor PFI-1 diminishes AR/AR-V7 signaling in prostate cancer cellsMarie C Hupe, M Raschid Hoda, Friedemann Zengerling, et al.
Urologia Internationalis|July 14, 2007
Cathepsin D serum levels are not a valid serum marker in renal cell carcinomaAxel S Merseburger, Joerg Hennenlotter, Arnulf Stenzl, et al.
Aktuelle Urologie|November 11, 2025
[New Prostate Cancer Guideline: Is Biopsy of PI-RADS 3 Lesions Meaningful? The Role of Multiparametric MRI-Ultrasound Fusion Biopsy in Detecting Clinically Significant Prostate Cancer]Paul Schildhauer, Marten Müller, Axel S Merseburger, et al.
Immunotherapy|July 20, 2010
Present state of target therapy for disseminated renal cell carcinomaSandra Waalkes, Mario Kramer, Thomas Rw Herrmann, et al.
Advances in Therapy|December 5, 2020
Hemopatch<sup>®</sup> as a Hemostatic Agent is Safe in Partial Nephrectomy: A Large, Single-Surgeon Retrospective EvaluationMarie C Hupe, Maximilian Büttner, Pouriya Faraj Tabrizi, et al.
World Journal of Urology|July 9, 2011
Natural orifice (NOTES) transurethral sutureless radical prostatectomy with thulium laser support: first patient reportUdo Nagele, Aristotelis G Anastasiadis, Ute Walcher, et al.
Oncology Letters|September 12, 2012
Maspin protein expression correlates with tumor progression in non-muscle invasive bladder cancerMario W Kramer, Sandra Waalkes, Jörg Hennenlotter, et al.
World Journal of Urology|September 28, 2014
Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?Axel S Merseburger, Peter Hammerer, Francois Rozet, et al.
Pageof 33